| abstract |
PROBLEM TO BE SOLVED: To contribute to the development of a novel strategy for immunotherapy of cancer, particularly melanoma, by examining the characteristics of melanoma antigen. The present invention provides a nucleic acid sequence encoding a melanoma antigen designated MART-1 that is recognized by T lymphocytes and is designated as an immunogenic peptide derived from the MART-1 and gp100. A second melanoma antigen is provided. Thereby, the provided proteins and peptides can be used as immunogens for the prevention or treatment of melanoma. [Selection figure] None |